Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis. // Surgical Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0960740426002513?dgcid=rss_sd_all
Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis. Surgical Oncology. https://www.sciencedirect.com/science/article/pii/S0960740426002513?dgcid=rss_sd_all
“Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis.” Surgical Oncology.
@article{article67010,
title = {Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis},
journal = {Surgical Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0960740426002513?dgcid=rss_sd_all}
}